Antibodies to CD40

Details for Australian Patent Application No. 2002356926 (hide)

International Classifications

Event Publications

27 March 2003 Complete Application Filed

Priority application(s): 60/348,980 09.11.01 US

24 July 2003 Application Open to Public Inspection

Published as AU-B-2002356926

22 July 2004 Amendment Made

The nature of the amendment is as shown in the statement(s) filed 21 May 2004

4 January 2007 Application Accepted

Published as AU-B-2002356926

14 June 2007 Section 223 Application Allowed

Pfizer Products Inc.; Abgenix, Inc. The time in which to file search results has been extended to 04 May 2007. Address for service in Australia - Cullen & Co Level 26 239 George Street Brisbane QLD 4000 2003

23 August 2007 Standard Patent Sealed

4 October 2007 Application for Amendment

The nature of the amendment is as shown in the statement(s) filed 27 Jul 2007. Address for service in Australia - Cullen & Co Level 26 239 George Street Brisbane QLD 4000 2003

14 February 2008 Amendment Made

The nature of the amendment is as shown in the statement(s) filed 27 Jul 2007

28 August 2008 Alteration of Name

The name of the patentee has been altered to Pfizer Products Inc.; Amgen Fremont Inc. 2003

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.